Nektar Gets $50M Deal From Amgen

11/2/10

Nektar Therapeutics (NASDAQ: NKTR), the San Carlos, CA-based biotech company, has struck a $50 million agreement to manufacture certain polymers for Amgen, according to a Reuters report. The polymers are a key ingredient in pegfilgrastim (Neulasta) a drug used to stimulate production of infection-fighting white blood cells in cancer patients suffering from the side effects of chemotherapy.

Luke Timmerman is the National Biotech Editor of Xconomy. E-mail him at ltimmerman@xconomy.com Follow @

Next Post

Related Topics

Related Posts

    

Xconomy Events Across the Network

The Napa Summit: Keeping America Growing

San Francisco · 6/7/12

More Xconomy Events

Xconomy’s Most Popular

  1. Biotech IPOs Start to Show Some Modest Signs of Life
  2. ASCO Preview: Eight Cancer Drugs to Watch at the Big Show
  3. Hey, Silicon Valley: Wake Up and Smell the Robots
  4. From MIT Entrepreneur to Tea Party Leader: The Thomas Massie Story
  5. Announcing Xconomy’s Napa Summit: Keeping America Growing

Xconomy on Demand

Did you miss something? Don't despair…

Xconomy offers a number of ways to subscribe for free!

Subscribe Now
IDG Tech Network
Protected by Mozy
Eventbrite - events made easy

Business, life sciences, and technology news — covering Boston, Seattle, San Diego, Detroit, San Francisco, New York and beyond.

© 2007-2012, Xconomy, Inc. Xconomy is a registered service mark of Xconomy, Inc. All rights reserved.

Site produced by Andrew Koyfman with design from Rob Hunter.